References
  1. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015;373(24):2336-2346.
  2. Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321-327.
  3. Kratz CP, Jongmans MC, Cavé H, et al. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. 2021;5(2):142-154.
  4. Kim J, Gianferante M, Karyadi DM, et al. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study. JNCI Cancer Spectrum. 2021;5(2).
  5. Sylvester DE, Chen Y, Jamieson RV, Dalla-Pozza L, Byrne JA. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature. J Med Genet. 2018;55(12):785-793.
  6. Postema FAM, Hopman SMJ, Aalfs CM, et al. Childhood tumours with a high probability of being part of a tumour predisposition syndrome; reason for referral for genetic consultation. Eur J Cancer. 2017;80:48-54.
  7. Minh T, Nguyen K, Behnert A, et al. Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. Fam Cancer. 2021;20:273-277.
  8. Druker H, Zelley K, McGee RB, Scollon SR, Kohlmann WK, Schneider KA, Wolfe Schneider K. Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient. Clin Cancer Res. 2017;23(13):e91–e97.
  9. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med.2015;17:405–24.
  10. Postema FAM, Hopman SMJ, Hennekam RC, Merks JHM. Consequences of diagnosing a tumor predisposition syndrome in children with cancer: A literature review. Pediatr Blood Cancer. 2018;65(1).
  11. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70-87.
  12. Ripperger T, Bielack SS, Borkhardt A, et al. Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173(4):1017-1037.
  13. Jongmans MCJ, Loeffen JLCM, Waanders E, et al. Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. Eur J Med Genet. 2016;59(3):116-125.
  14. Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD. The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatr Blood Cancer. 2017;64(8):e26441.
  15. Cullinan N, Schiller I, di Giuseppe G, et al. Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. J Clin Oncol. 2021;39(29):3207-3216.
  16. Goudie C, Witkowski L, Cullinan N, et al. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021;7(12):1.
  17. Rossini L, Durante C, Bresolin S, et al. Diagnostic strategies and algorithms for investigating cancer predisposition syndromes in children presenting with malignancy. Cancers. 2022;14(15):3741.
  18. Postema FAM, Hopman SMJ, de Borgie CAJM, et al. Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS): a prospective, observational, multi-center study. Fam Cancer. 2021;20(4):263-271.
  19. Wagener R, Taeubner J, Walter C, et al. Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer. Eur J Hum Genet. 2021;29(8):1301-1311.
  20. Gargallo P, Oltra S, Yáñez Y, et al. Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers. 2021;13(21).
  21. Fiala EM, Jayakumaran G, Mauguen A, et al. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nat Cancer. 2021;2(3):357-365.
  22. Chan SH, Chew W, Ishak ND, et al. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours. npj Genomic Medicine. 2018;3(1).
  23. Byrjalsen A, Hansen TV, Stoltze UK, et al. Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes. PLOS Genetics. 2020;16(12).
  24. Thariat J, Chevalier F, Orbach D, et al. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol. 2021;22(12).
  25. Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379-1386.
  26. Westdorp H, Kolders S, Hoogerbrugge N, et al. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 2017;403: 159-64.